Current and future prophylactic vaccines for hepatitis C virus

The development of a vaccine is necessary to combat the global hepatitis C virus (HCV) epidemic. The key to the development of a prophylactic vaccine is understanding the immune response in those who spontaneously resolve HCV infections versus those who develop chronic disease. Several promising vaccine candidates based on the use of viral vectors are currently in Phase I and Phase II clinical trials. The recently solved structures of the E2 glycoprotein have greatly aided epitope- and antibody-based vaccine design.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  2015-08-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/VDT.S48437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatitis C Virus Infection Associated With Administration of Intravenous Immune Globulin

  2017cited by this paper
• The candidate

  2016cited by this paper
• Structural Basis for Penetration of the Glycan Shield of Hepatitis C Virus E2 Glycoprotein by a Broadly Neutralizing Human Antibody*

  2015cited by this paper
• Computational tools for epitope vaccine design and evaluation.

  2015cited by this paper
• Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies

  2015cited by this paper
• Immune responses to HCV and other hepatitis viruses.

  2014influential reference
• Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses

  2014cited by this paper
• Structural Flexibility of a Conserved Antigenic Region in Hepatitis C Virus Glycoprotein E2 Recognized by Broadly Neutralizing Antibodies

  2014cited by this paper
• Combined Adenovirus Vector and Hepatitis C Virus Envelope Protein Prime-Boost Regimen Elicits T Cell and Neutralizing Antibody Immune Responses

  2014cited by this paper
• HCV E2 core structures and mAbs: something is still missing.

  2014cited by this paper
• Immune control and failure in HCV infection—tipping the balance

  2014cited by this paper
• The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection

  2014cited by this paper
• How hepatitis C virus invades hepatocytes: the mystery of viral entry.

  2014cited by this paper
• Non-random Escape Pathways from a Broadly Neutralizing Human Monoclonal Antibody Map to a Highly Conserved Region on the Hepatitis C Virus E2 Glycoprotein Encompassing Amino Acids 412–423

  2014cited by this paper
• Global Distribution and Prevalence of Hepatitis C Virus Genotypes

  2014cited by this paper
• Emerging Therapies for Hepatitis C

  2014cited by this paper
• Discrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralization

  2014influential reference
• Vertical transmission of hepatitis C virus: Current knowledge and perspectives.

  2014cited by this paper
• A View of the E2-CD81 Interface at the Binding Site of a Neutralizing Antibody against Hepatitis C Virus

  2014cited by this paper
• Recombinant Hepatitis C Virus Envelope Glycoprotein Vaccine Elicits Antibodies Targeting Multiple Epitopes on the Envelope Glycoproteins Associated with Broad Cross-Neutralization

  2014cited by this paper
• Unexpected structure for the N-terminal domain of hepatitis C virus envelope glycoprotein E1

  2014cited by this paper
• The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

  2014cited by this paper
• A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory

  2014cited by this paper
• Hepatitis C can be cured globally, but at what cost?

  2014cited by this paper
• Versatile convergent synthesis of a three peptide loop containing protein mimic of whooping cough pertactin by successive Cu(I)‐catalyzed azide alkyne cycloaddition on an orthogonal alkyne functionalized TAC‐scaffold

  2014cited by this paper
• Structure of the Core Ectodomain of the Hepatitis C Virus Envelope Glycoprotein 2

  2014cited by this paper
• Proof of principle for epitope-focused vaccine design

  2014cited by this paper
• Hepatitis C Virus E2 Envelope Glycoprotein Core Structure

  2013cited by this paper
• Prospects for prophylactic hepatitis C vaccines based on virus-like particles

  2013cited by this paper
• Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource

  2013cited by this paper
• Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning

  2013cited by this paper
• Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies.

  2013cited by this paper
• M2e-Displaying Virus-Like Particles with Associated RNA Promote T Helper 1 Type Adaptive Immunity against Influenza A

  2013cited by this paper
• Structural and Antigenic Definition of Hepatitis C Virus E2 Glycoprotein Epitopes Targeted by Monoclonal Antibodies

  2013influential reference
• Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells

  2013cited by this paper
• Structural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization Escape

  2013influential reference
• Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine

  2013cited by this paper
• Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1

  2012cited by this paper
• An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

  2012cited by this paper
• Toward a Hepatitis C Virus Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33, a Broadly Neutralizing Antibody

  2012cited by this paper
• Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus

  2012cited by this paper
• Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate

  2012cited by this paper
• Human Monoclonal Antibodies to a Novel Cluster of Conformational Epitopes on HCV E2 with Resistance to Neutralization Escape in a Genotype 2a Isolate

  2012cited by this paper
• Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees

  2012cited by this paper
• New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives

  2012cited by this paper
• Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus.

  2012cited by this paper
• A Blueprint for HIV Vaccine Discovery.

  2012cited by this paper
• Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C.

  2012cited by this paper
• Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion.

  2012cited by this paper
• Cooperativity in Virus Neutralization by Human Monoclonal Antibodies to Two Adjacent Regions Located at the Amino Terminus of Hepatitis C Virus E2 Glycoprotein

  2012cited by this paper
• Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man

  2012cited by this paper
• Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities

  2012cited by this paper
• Structure of Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Site 412 to 423 in Complex with Antibody AP33

  2012cited by this paper
• A siege of hepatitis: Immune boost for viral hepatitis

  2011cited by this paper
• Neutralizing Monoclonal Antibodies against Hepatitis C Virus E2 Protein Bind Discontinuous Epitopes and Inhibit Infection at a Postattachment Step

  2011cited by this paper
• A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

  2011cited by this paper
• The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity.

  2011cited by this paper
• T cell exhaustion

  2011cited by this paper
• Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2.

  2011cited by this paper
• Clearance of Genotype 1b Hepatitis C Virus in Chimpanzees in the Presence of Vaccine-Induced E1-Neutralizing Antibodies

  2011cited by this paper
• Mapping a Region of Hepatitis C Virus E2 That Is Responsible for Escape from Neutralizing Antibodies and a Core CD81-Binding Region That Does Not Tolerate Neutralization Escape Mutations

  2011cited by this paper
• Hepatitis C Virus Is Primed by CD81 Protein for Low pH-dependent Fusion*

  2011cited by this paper
• The Hepatitis C Virus Glycan Shield and Evasion of the Humoral Immune Response

  2011cited by this paper
• Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection.

  2010cited by this paper
• Mutations within a Conserved Region of the Hepatitis C Virus E2 Glycoprotein That Influence Virus-Receptor Interactions and Sensitivity to Neutralizing Antibodies

  2010cited by this paper
• Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.

  2010cited by this paper
• Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes

  2010cited by this paper
• Hypervariable Region 1 Differentially Impacts Viability of Hepatitis C Virus Strains of Genotypes 1 to 6 and Impairs Virus Neutralization

  2010cited by this paper
• Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.

  2010cited by this paper
• Clearance of hepatitis C in chimpanzees is associated with intrahepatic T‐cell perforin expression during the late acute phase

  2010cited by this paper
• Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine.

  2010cited by this paper
• Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV

  2010cited by this paper
• Characterization of the Envelope Glycoproteins Associated with Infectious Hepatitis C Virus

  2010influential reference
• Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus.

  2009cited by this paper
• Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men.

  2009cited by this paper
• Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures

  2009cited by this paper
• Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers

  2009cited by this paper
• The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell Response1

  2009cited by this paper
• The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD 8 T Cell Response 1

  2009cited by this paper
• HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality

  2009cited by this paper
• Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV‐infected CD20‐positive B‐cell lymphoma undergoing rituximab combination chemotherapy

  2008cited by this paper
• Evidence for Protection against Chronic Hepatitis C Virus Infection in Chimpanzees by Immunization with Replicating Recombinant Vaccinia Virus

  2008cited by this paper
• Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

  2008cited by this paper
• Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein

  2008cited by this paper
• Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.

  2008cited by this paper
• Hepatitis C Virus Envelope Glycoprotein E2 Glycans Modulate Entry, CD81 Binding, and Neutralization

  2007cited by this paper
• Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8+ TEMRA Cells in Early Infection Are Linked to Control of HIV-1 Viremia and Predict the Subsequent Viral Load Set Point

  2007cited by this paper
• Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.

  2007cited by this paper
• Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C

  2007cited by this paper
• Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and T‐helper epitopes

  2007cited by this paper
• Vaccine‐induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD‐1 and chronicity

  2007cited by this paper
• Expression and Characterization of a Minimal Hepatitis C Virus Glycoprotein E2 Core Domain That Retains CD81 Binding

  2007cited by this paper
• Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees

  2007cited by this paper
• Flying under the radar: the immunobiology of hepatitis C.

  2007cited by this paper
• Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.

  2007cited by this paper
• Hepatitis C virus cell‐cell transmission in hepatoma cells in the presence of neutralizing antibodies

  2007cited by this paper
• Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming–boosting with novel adenoviral vectors based on different serotypes

  2006cited by this paper
• Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies

  2006cited by this paper
• A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees

  2006cited by this paper
• High Density Lipoprotein Inhibits Hepatitis C Virus-neutralizing Antibodies by Stimulating Cell Entry via Activation of the Scavenger Receptor BI*

  2006cited by this paper

• Challenges in coverage of future hepatitis C vaccines: Review and potential solutions.

  2025cites this paper
• Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine Development

  2024cites this paper
• Upstream and Downstream Processes for Viral Nanoplexes as Vaccines.

  2021cites this paper
• Broad Spectrum Peptide Vaccine Design Against Hepatitis C Virus.

  2019cites this paper
• Computational design of hepatitis C virus immunogens from host-pathogen dynamics over empirical viral fitness landscapes

  2018cites this paper
• Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus

  2018cites this paper
• Predicting the Effectiveness of Hepatitis C Virus Neutralizing Antibodies by Bioinformatic Analysis of Conserved Epitope Residues Using Public Sequence Data

  2018cites this paper
• Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope

  2017cites this paper
• Global elimination of hepatitis C virus infection: Progresses and the remaining challenges

  2017cites this paper
• Lettuce‐produced hepatitis C virus E1E2 heterodimer triggers immune responses in mice and antibody production after oral vaccination

  2017cites this paper
• Association between serum aminotransferase enzymes–lipid profile ratio and spontaneous HCV clearance in blood donors

  2016cites this paper
• Viral evasion and challenges of hepatitis C virus vaccine development.

  2016cites this paper